| Symbol | IRWD |
|---|---|
| Name | IRONWOOD PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 100 SUMMER STREET, SUITE 2300, BOSTON, MA 02110 |
| Telephone | 617-621-7722 |
| Fax | — |
| — | |
| Website | https://www.ironwoodpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001446847 |
| Description | Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. Additional info from NASDAQ: |
2026-08-07 10:59
New Form SCHEDULE 13G - IRONWOOD PHARMACEUTICALS INC <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000487 <b>Size:</b> 7 KB
Read more
2026-08-06 11:05
Ironwood - Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Read more
2026-08-06 11:05
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Read more
2026-07-30 20:05
Ironwood - Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Read more
2026-07-30 20:05
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Read more
2026-07-22 20:10
Silber Jeffrey 🟢 acquired 137.0K shares of IRONWOOD PHARMACEUTICALS INC (IRWD) Transaction Date: Jul 20, 2026 | Filing ID: 312410
Read more
2026-07-14 11:30
Ironwood - Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
Read more
2026-06-17 20:47
Shepard Jay 🟢 acquired 63.5K shares of IRONWOOD PHARMACEUTICALS INC (IRWD) Transaction Date: Jun 16, 2026 | Filing ID: 274301
Read more
2026-06-17 20:45
Kessler Marla L 🟢 acquired 63.5K shares of IRONWOOD PHARMACEUTICALS INC (IRWD) Transaction Date: Jun 16, 2026 | Filing ID: 274292
Read more
2026-06-17 20:44
Currie Mark G 🟢 acquired 63.5K shares of IRONWOOD PHARMACEUTICALS INC (IRWD) Transaction Date: Jun 16, 2026 | Filing ID: 274288
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05760313 | A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Pa… | Phase2 | Functional Constipation | Completed | 2023-04-27 | 2025-06-09 | ClinicalTrials.gov |
| NCT05740007 | A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With I… | Phase2 | Interstitial Cystitis | Terminated | 2023-03-28 | 2025-02-06 | ClinicalTrials.gov |
| NCT05362695 | A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects | Phase1 | Healthy Volunteers | Completed | 2022-05-17 | 2022-07-13 | ClinicalTrials.gov |
| NCT05188261 | A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2022-01-18 | 2022-03-21 | ClinicalTrials.gov |
| NCT04166058 | Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C | Phase3 | Irritable Bowel Syndrome With Constipation | Completed | 2019-11-19 | 2025-06-05 | ClinicalTrials.gov |
| NCT04110145 | Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional… | Phase2 | Functional Constipation | Completed | 2019-10-14 | 2021-04-20 | ClinicalTrials.gov |
| NCT04026113 | Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age… | Phase3 | Functional Constipation | Completed | 2019-10-01 | 2024-05-29 | ClinicalTrials.gov |
| NCT03931785 | A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominan… | Phase2 | Irritable Bowel Syndrome With Diarrhea (IBS-D) | Completed | 2019-05-01 | 2020-03-11 | ClinicalTrials.gov |
| NCT03856970 | Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contrac… | Phase1 | Healthy Volunteers | Completed | 2019-03-11 | 2019-07-03 | ClinicalTrials.gov |
| NCT03561883 | Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflu… | Phase3 | Gastroesophageal Reflux Disease (GERD) | Completed | 2018-09-06 | 2020-11-06 | ClinicalTrials.gov |
| NCT03561090 | A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Ref… | Phase3 | Gastroesophageal Reflux Disease (GERD) | Terminated | 2018-06-20 | 2020-11-03 | ClinicalTrials.gov |
| NCT03573908 | A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Co… | Phase3 | Irritable Bowel Syndrome Characterized by Constipation | Completed | 2018-06-20 | 2019-04-10 | ClinicalTrials.gov |
| NCT03226899 | A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participant… | Phase4 | Gout | Terminated | 2017-07-19 | 2019-02-25 | ClinicalTrials.gov |
| NCT02837783 | A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Ir… | Phase4 | Irritable Bowel Syndrome Characterized by Constipation | Terminated | 2016-12-21 | 2018-10-31 | ClinicalTrials.gov |
| NCT02637557 | A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Re… | Phase2 | Gastroesophageal Reflux Disease | Completed | 2016-03-01 | 2017-04-26 | ClinicalTrials.gov |
| NCT02559570 | A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally… | Phase2 | Functional Constipation in Children Ages 6-17 Years | Completed | 2015-11-03 | 2018-05-29 | ClinicalTrials.gov |
| NCT02559817 | A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally… | Phase2 | Irritable Bowel Syndrome With Constipation | Terminated | 2015-11-01 | 2019-08-30 | ClinicalTrials.gov |
| NCT02590432 | An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linacl… | Phase4 | Irritable Bowel Syndrome With Constipation | Completed | 2015-11-01 | 2018-02-05 | ClinicalTrials.gov |
| NCT02559206 | Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipatio… | Phase2 | Irritable Bowel Syndrome With Constipation | Completed | 2015-10-22 | 2016-09-30 | ClinicalTrials.gov |
| NCT02270983 | Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of L… | Phase2 | Opioid-Induced Constipation | Completed | 2014-10-31 | 2015-10-31 | ClinicalTrials.gov |
| NCT02289846 | Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) | Phase2 | Diabetic Gastroparesis | Completed | 2014-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02291679 | Trial of Linaclotide in Patients With Chronic Idiopathic Constipation | Phase3 | Chronic Idiopathic Constipation | Completed | 2014-10-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02144376 | MRI and Microbiota Analysis in Constipation | Na | Constipation | Completed | 2014-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02030925 | Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Com… | Phase2 | Gastroesophageal Reflux | Completed | 2014-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01880424 | A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-contro… | Phase3 | Irritable Bowel Syndrome With Constipation (IBS-C) | Completed | 2013-07-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01805999 | Ispaghula and Colonic Water Content | Na | Healthy | Completed | 2013-03-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01712412 | Phase 2a Study of IW-9179 to Treat Functional Dyspepsia | Phase2 | Dyspepsia | Terminated | 2012-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01642914 | Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Pr… | Phase3 | Chronic Constipation | Completed | 2012-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01107236 | Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third M… | Phase2 | Healthy | Completed | 2010-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00948818 | Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome Wit… | Phase3 | Irritable Bowel Syndrome Characterized by Constipation | Completed | 2009-07-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00938717 | Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipatio… | Phase3 | Irritable Bowel Syndrome With Constipation | Completed | 2009-07-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00765999 | An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic C… | Phase3 | Chronic Constipation | Completed | 2008-10-31 | 2012-01-31 | ClinicalTrials.gov |
| NCT00730171 | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic C… | Phase3 | Irritable Bowel Syndrome With Constipation | Completed | 2008-09-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00765882 | Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide A… | Phase3 | Chronic Constipation | Completed | 2008-09-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00730015 | Trial of Linaclotide in Patients With Chronic Constipation | Phase3 | Chronic Constipation | Completed | 2008-08-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00460811 | Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Admi… | Phase2 | Irritable Bowel Syndrome With Constipation | Completed | 2007-04-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00402337 | Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to P… | Phase2 | Chronic Constipation | Completed | 2006-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00404001 | Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia | Phase2 | Hypercholesterolemia | Completed | 2006-11-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00306748 | Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting C… | Phase2 | Constipation | Completed | 2006-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00258193 | Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C… | Phase2 | Irritable Bowel Syndrome | Completed | 2006-01-01 | 2006-09-01 | ClinicalTrials.gov |
Total clinical trials: 40
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Matching Placebo | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT02289846 |
| IW-9179 | Other | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT02289846 |
| corticosteroids | Other | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| colchicine | Other | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| Placebo | Other | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| XOI | Other | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| Lesinurad | Other | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| Placebo for Linaclotide | Other | Phase PHASE3 | Functional Constipation (FC) | COMPLETED | NCT05652205 |
| Linaclotide | Other | Phase PHASE3 | Functional Constipation (FC) | COMPLETED | NCT05652205 |
| Placebo | Other | Phase PHASE2 | Dyspepsia | TERMINATED | NCT01712412 |
| IW-9179 | Other | Phase PHASE2 | Dyspepsia | TERMINATED | NCT01712412 |
| Matching placebo | Other | Phase PHASE3 | Chronic Constipation | COMPLETED | NCT01642914 |
| Linaclotide 145 micrograms | Other | Phase PHASE3 | Chronic Constipation | COMPLETED | NCT01642914 |
| Linaclotide 290 micrograms | Other | Phase PHASE3 | Chronic Constipation | COMPLETED | NCT01642914 |
| Matching Placebo | Other | Phase PHASE2 | Gastroesophageal Reflux | COMPLETED | NCT02030925 |
| IW-3718 | Other | Phase PHASE2 | Gastroesophageal Reflux | COMPLETED | NCT02030925 |
| Linaclotide | Other | Phase PHASE3 | Irritable Bowel Syndrome With Constipation (IBS-C) | COMPLETED | NCT01880424 |
| Placebo | Other | Phase PHASE3 | Irritable Bowel Syndrome With Constipation (IBS-C) | COMPLETED | NCT01880424 |
| Maltodextrin | Other | Approved | Constipation | COMPLETED | NCT02144376 |
| Ispaghula | Other | Approved | Constipation | COMPLETED | NCT02144376 |
| 3.5g Ispaghula + 3.5 g placebo | Other | Approved | Healthy | COMPLETED | NCT01805999 |
| 7 g placebo | Other | Approved | Healthy | COMPLETED | NCT01805999 |
| 7 g Ispaghula | Other | Approved | Healthy | COMPLETED | NCT01805999 |
| Matching Placebo | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT02291679 |
| Linaclotide | Other | Phase PHASE3 | Chronic Idiopathic Constipation | COMPLETED | NCT02291679 |
| Placebo | Other | Phase PHASE2 | Opioid-Induced Constipation | COMPLETED | NCT02270983 |
| Linaclotide 290 micrograms | Other | Phase PHASE2 | Opioid-Induced Constipation | COMPLETED | NCT02270983 |
| Linaclotide 145 micrograms | Other | Phase PHASE2 | Opioid-Induced Constipation | COMPLETED | NCT02270983 |
| LIN 145 µg | Other | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| LIN Dose C | Other | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| LIN Dose B | Other | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| LIN Dose A | Other | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| Placebo | Other | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| IW-3718 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Glyburide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Levothyroxine | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Microgestin® | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Linaclotide | Other | Phase PHASE4 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT02590432 |
| PPI | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT02637557 |
| Matching Placebo | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT02637557 |
| IW-3718 | Other | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT02637557 |
| Matching Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT02559206 |
| Linaclotide | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT02559206 |
| Placebo | Other | Phase PHASE3 | Irritable Bowel Syndrome Characterized by Constipation | COMPLETED | NCT03573908 |
| Linaclotide | Other | Phase PHASE3 | Irritable Bowel Syndrome Characterized by Constipation | COMPLETED | NCT03573908 |
| Matching Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| Linaclotide Approved Adult Dose | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| Linaclotide Dose C | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| Linaclotide Dose B | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| Linaclotide Dose A | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome With Diarrhea (IBS-D) | COMPLETED | NCT03931785 |
| MD-7246 | Other | Phase PHASE2 | Irritable Bowel Syndrome With Diarrhea (IBS-D) | COMPLETED | NCT03931785 |
| Standard-dose PPIs QD | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT03561883 |
| placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT03561883 |
| IW-3718 | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT03561883 |
| Standard-dose PPIs QD | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | TERMINATED | NCT03561090 |
| placebo | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | TERMINATED | NCT03561090 |
| IW-3718 | Other | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | TERMINATED | NCT03561090 |
| Placebo | Other | Phase PHASE4 | Irritable Bowel Syndrome Characterized by Constipation | TERMINATED | NCT02837783 |
| Linaclotide | Other | Phase PHASE4 | Irritable Bowel Syndrome Characterized by Constipation | TERMINATED | NCT02837783 |
| Placebo | Other | Phase PHASE2 | Functional Constipation | COMPLETED | NCT04110145 |
| Linaclotide | Other | Phase PHASE2 | Functional Constipation | COMPLETED | NCT04110145 |
| Naproxen Sodium | Other | Phase PHASE2 | Healthy | COMPLETED | NCT01107236 |
| Matching Placebo | Other | Phase PHASE2 | Healthy | COMPLETED | NCT01107236 |
| IW-6118 | Other | Phase PHASE2 | Healthy | COMPLETED | NCT01107236 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05188261 |
| IW-3300 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05188261 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05362695 |
| IW-3300 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05362695 |
| Placebo | Other | Phase PHASE3 | Functional Constipation | COMPLETED | NCT04026113 |
| Linaclotide | Other | Phase PHASE3 | Functional Constipation | COMPLETED | NCT04026113 |
| Placebo | Other | Phase PHASE2 | Interstitial Cystitis | TERMINATED | NCT05740007 |
| IW-3300 rectal foam | Other | Phase PHASE2 | Interstitial Cystitis | TERMINATED | NCT05740007 |
| Placebo | Other | Phase PHASE2 | Functional Constipation | COMPLETED | NCT05760313 |
| Linaclotide | Other | Phase PHASE2 | Functional Constipation | COMPLETED | NCT05760313 |
| Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | Other | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT04166058 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) | Other | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT04166058 |
| Virtual Reality | Other | Approved | Irritable Bowel Syndrome With Constipation | RECRUITING | NCT05796388 |
| Virtual Reality | DEVICE | Approved | Irritable Bowel Syndrome With Constipation | RECRUITING | NCT05796388 |
| IW-3300 rectal foam | DRUG | Phase PHASE2 | Interstitial Cystitis | TERMINATED | NCT05740007 |
| Placebo for Linaclotide | DRUG | Phase PHASE3 | Functional Constipation (FC) | COMPLETED | NCT05652205 |
| IW-3300 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05362695 |
| Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | DRUG | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT04166058 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) | DRUG | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT04166058 |
| MD-7246 | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Diarrhea (IBS-D) | COMPLETED | NCT03931785 |
| Digoxin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Glyburide | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Levothyroxine | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Microgestin® | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| Standard-dose PPIs QD | DRUG | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT03561883 |
| placebo | DRUG | Phase PHASE3 | Gastroesophageal Reflux Disease (GERD) | COMPLETED | NCT03561883 |
| corticosteroids | DRUG | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| colchicine | DRUG | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| XOI | DRUG | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| Lesinurad | DRUG | Phase PHASE4 | Gout | TERMINATED | NCT03226899 |
| PPI | DRUG | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT02637557 |
| Linaclotide Approved Adult Dose | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| Linaclotide Dose C | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| Linaclotide Dose B | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| Linaclotide Dose A | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT02559817 |
| LIN 145 µg | DRUG | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| LIN Dose C | DRUG | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| LIN Dose B | DRUG | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| LIN Dose A | DRUG | Phase PHASE2 | Functional Constipation in Children Ages 6-17 Years | COMPLETED | NCT02559570 |
| IW-9179 | DRUG | Phase PHASE2 | Diabetic Gastroparesis | COMPLETED | NCT02289846 |
| IW-3718 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03856970 |
| MD-0727 | DRUG | Phase PHASE2 | Hypercholesterolemia | COMPLETED | NCT00404001 |
| Naproxen Sodium | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT01107236 |
| IW-6118 | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT01107236 |
| Linaclotide or Matching Placebo | DRUG | Phase PHASE3 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT00938717 |
| Placebo | DRUG | Phase PHASE2 | Functional Constipation | COMPLETED | NCT05760313 |
| Linaclotide 145 micrograms | DRUG | Phase PHASE2 | Opioid-Induced Constipation | COMPLETED | NCT02270983 |
| Linaclotide 290 micrograms | DRUG | Phase PHASE2 | Opioid-Induced Constipation | COMPLETED | NCT02270983 |
| Linaclotide | DRUG | Phase PHASE2 | Functional Constipation | COMPLETED | NCT05760313 |
| Matching Placebo | DRUG | Phase PHASE2 | Gastroesophageal Reflux Disease | COMPLETED | NCT02637557 |
| Linaclotide Acetate | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | COMPLETED | NCT00460811 |
| Matching placebo | DRUG | Phase PHASE3 | Chronic Constipation | COMPLETED | NCT01642914 |
| linaclotide acetate | DRUG | Phase PHASE2 | Chronic Constipation | COMPLETED | NCT00402337 |
| MD-1100 Acetate | DRUG | Phase PHASE2 | Constipation | COMPLETED | NCT00306748 |
Total products: 120